×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| CIPLA LTD. | 53172.4 | 13031.3 | 50461.7 | 16.12 | 1,26,082 | 23.4 |
| TORRENT PHARMACEUTICALS LTD. | 26110.0 | 5510.0 | 26160.0 | 16.28 | 121226 | 60.0 |
| Max Healthcare Institute Limit | 7738.7 | 1660.3 | 6940.2 | 1.7 | 114616 | 95.6 |
Cipla Ltd.,, with Security Code 500087, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,893.7 | 4,318.2 | 4,664.7 | 4,381.3 | 4,036.7 | 4,501.1 | 4,775.0 | 4,970.9 | 4,797.9 | 5,046.2 |
| Expenses | 3,094.0 | 3,113.5 | 3,285.6 | 3,025.5 | 3,208.8 | 3,141.2 | 3,337.0 | 3,309.1 | 3,479.1 | 3,421.7 |
| Operating Profit | 799.8 | 1,204.7 | 1,379.1 | 1,355.9 | 827.9 | 1,359.9 | 1,438.0 | 1,661.8 | 1,318.8 | 1,624.5 |
| OPM % | 20.54% | 27.9% | 29.56% | 30.95% | 20.51% | 30.21% | 30.12% | 33.43% | 27.49% | 32.19% |
| Other Income | -66.2 | 158.0 | 205.1 | 169.0 | 538.6 | 213.5 | 289.1 | 188.7 | 588.0 | 271.1 |
| Interest | 10.5 | 0.3 | 7.8 | 9.1 | 5.5 | 5.1 | 3.0 | 3.6 | 3.5 | 5.9 |
| Depreciation | 161.6 | 136.0 | 179.8 | 135.0 | 136.8 | 137.9 | 145.7 | 142.6 | 147.7 | 145.7 |
| Profit before tax | 747.5 | 1,226.4 | 1,396.6 | 1,380.8 | 1,224.2 | 1,430.5 | 1,578.5 | 1,704.4 | 1,461.0 | 1,744.0 |
| Tax % | -36.7% | -27% | -26.3% | -26.3% | -19.8% | -26.2% | -25.4% | 15.6% | -15.4% | 25.3% |
| Net Profit | 355.5 | 895.0 | 1,029.7 | 1,114.1 | 1,038.4 | 1,055.9 | 1,178.2 | 1,438.2 | 1,485.4 | 1,303.1 |
| EPS in Rs | 4.4 | 11.08 | 12.75 | 13.79 | 12.85 | 13.07 | 14.58 | 17.79 | 0 | 16.12 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,810.1 | 5,739.3 | 6,328.9 | 6,678.2 | 6,603.8 | 6,163.2 | 6,693.9 | 7,051.0 | 7,073.0 | 6,729.7 |
| Expenses | 4,402.8 | 4,567.2 | 4,835.0 | 4,944.9 | 4,856.4 | 4,849.9 | 4,978.1 | 5,166.4 | 5,093.2 | 5,202.9 |
| Operating Profit | 1,407.3 | 1,172.1 | 1,493.9 | 1,733.3 | 1,747.4 | 1,313.3 | 1,715.8 | 1,884.6 | 1,979.8 | 1,526.8 |
| OPM % | 24.22% | 20.42% | 23.6% | 25.95% | 26.46% | 21.31% | 25.63% | 26.73% | 27.99% | 22.69% |
| Other Income | 114.4 | -47.8 | 136.3 | 176.3 | -10.2 | 249.3 | 160.2 | 190.6 | 221.6 | 289.5 |
| Interest | 31.8 | 34.4 | 16.4 | 25.8 | 30.1 | 17.6 | 18.0 | 15.4 | 14.6 | 14.0 |
| Depreciation | 272.1 | 346.2 | 239.2 | 290.0 | 233.4 | 288.3 | 246.7 | 271.7 | 279.8 | 308.7 |
| Profit before tax | 1,217.8 | 926.2 | 1,374.6 | 1,593.8 | 1,668.5 | 1,256.7 | 1,611.4 | 1,788.1 | 1,907.0 | 1,493.5 |
| Tax % | -33.7% | -29.8% | -27.5% | -27.5% | -27.5% | -25.8% | 27% | -27% | -17.3% | -18.6% |
| Net Profit | 807.8 | 521.5 | 998.1 | 1,155.4 | 1,068.4 | 931.9 | 1,175.5 | 1,305.0 | 1,574.6 | 1,214.1 |
| EPS in Rs | 9.92 | 6.51 | 12.33 | 14 | 13.07 | 11.62 | 14.57 | 16.12 | 19.43 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 7% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 19% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 18% |
| 3 Years: | 15% |
| 1 Year: | -1% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 30% |
| 3 Years: | 27% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 18% |
| 3 Years: | 15% |
| 1 Year: | -1% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|